JP2021524451A5 - - Google Patents
Info
- Publication number
- JP2021524451A5 JP2021524451A5 JP2020564553A JP2020564553A JP2021524451A5 JP 2021524451 A5 JP2021524451 A5 JP 2021524451A5 JP 2020564553 A JP2020564553 A JP 2020564553A JP 2020564553 A JP2020564553 A JP 2020564553A JP 2021524451 A5 JP2021524451 A5 JP 2021524451A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide chain
- seq
- acid sequence
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673462P | 2018-05-18 | 2018-05-18 | |
| US62/673,462 | 2018-05-18 | ||
| PCT/US2019/032030 WO2019222104A1 (en) | 2018-05-18 | 2019-05-13 | Optimized gp41-binding molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524451A JP2021524451A (ja) | 2021-09-13 |
| JP2021524451A5 true JP2021524451A5 (https=) | 2022-05-16 |
Family
ID=68540936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564553A Pending JP2021524451A (ja) | 2018-05-18 | 2019-05-13 | 最適化済みｇｐ４１結合分子及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210246194A1 (https=) |
| EP (1) | EP3794027A4 (https=) |
| JP (1) | JP2021524451A (https=) |
| CN (1) | CN112533945A (https=) |
| AU (1) | AU2019269383A1 (https=) |
| BR (1) | BR112020023432A2 (https=) |
| CA (1) | CA3100398A1 (https=) |
| IL (1) | IL278832A (https=) |
| MX (1) | MX2020012309A (https=) |
| SG (1) | SG11202011355QA (https=) |
| WO (1) | WO2019222104A1 (https=) |
| ZA (1) | ZA202007056B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035419B9 (ru) * | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| MX375669B (es) * | 2014-09-26 | 2025-03-06 | Macrogenics Inc | Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos. |
| KR20200098590A (ko) | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
| CN111647078B (zh) * | 2020-06-22 | 2022-04-26 | 中国医学科学院医学生物学研究所 | 一种抗hiv的单克隆抗体及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3124497B1 (en) * | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| SMT202100464T1 (it) * | 2013-03-14 | 2021-11-12 | Macrogenics Inc | Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione |
| US9988438B2 (en) * | 2013-07-25 | 2018-06-05 | Board of Supervisor of Louisiana State University and Agricultural and Mechanical College | Anti-HIV dual specificity antibodies and methods of HIV treatment |
| UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| EA035419B9 (ru) * | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| MX386297B (es) * | 2014-09-29 | 2025-03-18 | Univ Duke | Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1. |
| CN107847591B (zh) * | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| MX2018014950A (es) * | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
-
2019
- 2019-05-13 EP EP19802868.0A patent/EP3794027A4/en active Pending
- 2019-05-13 CN CN201980048041.9A patent/CN112533945A/zh active Pending
- 2019-05-13 JP JP2020564553A patent/JP2021524451A/ja active Pending
- 2019-05-13 SG SG11202011355QA patent/SG11202011355QA/en unknown
- 2019-05-13 AU AU2019269383A patent/AU2019269383A1/en not_active Abandoned
- 2019-05-13 CA CA3100398A patent/CA3100398A1/en active Pending
- 2019-05-13 BR BR112020023432-0A patent/BR112020023432A2/pt not_active IP Right Cessation
- 2019-05-13 US US17/055,805 patent/US20210246194A1/en active Pending
- 2019-05-13 MX MX2020012309A patent/MX2020012309A/es unknown
- 2019-05-13 WO PCT/US2019/032030 patent/WO2019222104A1/en not_active Ceased
-
2020
- 2020-11-12 ZA ZA2020/07056A patent/ZA202007056B/en unknown
- 2020-11-18 IL IL278832A patent/IL278832A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Bispecific antibodies: from research to clinical application | |
| Hosseini et al. | Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials | |
| Riethmüller | Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on | |
| JP2021524451A5 (https=) | ||
| JP2020055858A5 (https=) | ||
| JP2023106433A5 (https=) | ||
| JP2022510218A5 (https=) | ||
| JP2021098732A5 (https=) | ||
| JP2020529410A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021524267A5 (https=) | ||
| JP2021522162A5 (https=) | ||
| IL271325B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| JP2019536430A5 (https=) | ||
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| JP2016536322A5 (https=) | ||
| JP2018533371A5 (https=) | ||
| JP2022551081A5 (https=) | ||
| RU2016114504A (ru) | Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2022505445A5 (https=) | ||
| JP2022515152A5 (https=) | ||
| JP2024507540A5 (https=) | ||
| JP2023551535A5 (https=) | ||
| JP2023506834A5 (https=) |